Post-Conference Workshop Day

This workshop will explore how artificial intelligence and machine learning are transforming ADC target identification and screening, payload optimisation, and toxicity prediction within model systems. Discuss practical implementation challenges, data requirements, and regulatory considerations for AI-driven approaches.

Key Questions:

• How can AI improve target risk assessment and reduce preclinical attrition?
• What data sets are required to build predictive toxicity models?
• What are the limitations of current AI approaches in ADC development?

Case Study Includes:

• Integrating AI for Advancing ADC Development – A New Tool in the Biologist’s Playbook

In today’s increasingly crowded ADC landscape, savvy IP strategy is critical for commercial success. This workshop explores how innovators can identify the IP opportunities and risks when developing a novel conjugate asset. Gain practical insights into competitive IP positioning, covering the type and timing of your own IP creation, as well as how to manage freedom-to-operate challenges. The workshop will demonstrate how to use IP strategy to enable your ADC or conjugate asset to reach its full commercial potential.

Key Questions:

• Reviewing approaches for leveraging known technology to minimise patent infringement risk
• Understanding the risks and opportunities of using known technology as the starting point for innovation
• Exploring strategies for protecting novel ADC assets and position them to withstand competitive challenges

As novel ADCs push beyond the boundaries of traditional therapies, bioanalytical teams face growing challenges in determining what to measure, why it matters, and how to generate meaningful data. This workshop will explore the evolving strategies needed to overcome analytical complexities, navigate limited regulatory guidance, and support the successful translation of next-generation modalities into the clinic.

Topics covered can include:

• Exploring clinical bioanalytical strategies in the absence of modality-specific regulatory guidance
• Overcoming bioanalytical challenges for novel conjugates, including assay development, measurement complexity, and generating clinically meaningful data
• Tailoring measurement approaches across diverse modalities for non-traditional ADCs, immune stimulatory antibody conjugates, and antibody-oligonucleotide conjugates.